Skip to main content

Portage Biotech Stock Forecast, Price & News

-0.33 (-1.18 %)
(As of 05/12/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume18,429 shs
Average Volume11,136 shs
Market Capitalization$333.25 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive PRTG News and Ratings via Email

Sign-up to receive the latest news and ratings for Portage Biotech and its competitors with MarketBeat's FREE daily newsletter.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.


See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:PRTG
Phone416 929 1806
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$333.25 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

2034th out of 2,042 stocks

Biotechnology Industry

155th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Portage Biotech (NASDAQ:PRTG) Frequently Asked Questions

What stocks does MarketBeat like better than Portage Biotech?

Wall Street analysts have given Portage Biotech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Portage Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Portage Biotech's key executives?

Portage Biotech's management team includes the following people:
  • Dr. Ian B. Walters, CEO & Director (Age 53, Pay $350k)
  • Mr. Allan J. Lee Shaw CPA, Chief Financial Officer (Age 57)
  • Mr. Steve Innaimo, VP of Project Management & Operations
  • Dr. Robert A. Kramer Ph.D., Chief Scientific Officer

Who are some of Portage Biotech's key competitors?

What is Portage Biotech's stock symbol?

Portage Biotech trades on the NASDAQ under the ticker symbol "PRTG."

How do I buy shares of Portage Biotech?

Shares of PRTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Portage Biotech's stock price today?

One share of PRTG stock can currently be purchased for approximately $27.58.

How much money does Portage Biotech make?

Portage Biotech has a market capitalization of $333.25 million.

What is Portage Biotech's official website?

The official website for Portage Biotech is

How can I contact Portage Biotech?

The company can be reached via phone at 416 929 1806.

This page was last updated on 5/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.